- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05175742
PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.
A Phase 2, Randomized, Double-dummy, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Compared to Pfizer-BioNTech COVID-19 Vaccine in Healthy Seronegative Adults Aged 18 to 64 Years
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2H 2G4
- LMC Clinical Research Inc. (Calgary)
-
-
Ontario
-
Mississauga, Ontario, Canada, L4V1P1
- Malton Medical
-
Ottawa, Ontario, Canada, K1H 1E4
- Red Maple
-
Toronto, Ontario, Canada, M1S3V6
- Pharma Medica Research Inc.
-
Toronto, Ontario, Canada, M4G3E8
- Manna Bayview
-
Toronto, Ontario, Canada, M9W4L6
- Manna Toronto
-
-
-
-
Gauten
-
Johannesburg, Gauten, South Africa, 1864
- Wits Vaccines & Infections Diseases Analytics (VIDA) Research Unit
-
-
Mpumalanga
-
Middleburg, Mpumalanga, South Africa, 1055
- MERC Middleburg
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7500
- TREAD Research
-
Cape Town, Western Cape, South Africa, 7700
- UCT Lung institute
-
Paarl, Western Cape, South Africa, 7626
- Be Part Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Each subject must meet the following criteria to be enrolled and randomized into the study:
- Willing and able to provide written informed consent to participate prior to commencing any study-related activities.
- Must be able to attend all visits (scheduled and unscheduled, as applicable) for the duration of the study and comply with all study procedures.
- Healthy adult males and females 18 to 64 years of age, inclusive, at Screening Visit (Visit 1).
- Negative to SARS-CoV-2 (COVID-19 disease) at screening and at each dosing, without evidence of recent of exposure or viral respiratory disease not identified as influenza or respiratory syncytial virus (RSV) (febrile or lower respiratory tract infection).
- Must be in general good health before study participation with no clinically relevant abnormalities that could interfere with study assessments at investigator's discretion. Subjects may have stable comorbidities (no change in medications, exacerbations, or hospitalizations in past three (3) months).
Women of childbearing potential (WOCBP) and men whose sexual partners are WOCBP must be able and willing to use at least one (1) highly effective method of contraception (i.e., including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy, hormonal oral [in combination with male condoms with spermicide], transdermal, implant, or injection, barrier [i.e., condom, diaphragm with spermicide]; intrauterine device; vasectomized partner [six months minimum], clinically sterile partner; or abstinence) during the study.
- A female subject is considered a WOCBP after menarche and until she is in a postmenopausal state for 12 consecutive months (without an alternative medical cause) or otherwise permanently sterile.
Subjects not of childbearing potential are not required to use any other forms of contraception during the study. Non-childbearing potential is defined as subject confirmed:
- Surgical sterilization (e.g., bilateral oophorectomy, bilateral salpingectomy, bilateral occlusion by cautery, hysterectomy, or tubal ligation).
- Postmenopausal (defined as permanent cessation of menstruation for at least 12 consecutive months prior to screening); if postmenopausal status is unclear, pregnancy tests will be performed prior to vaccinations.
WOCBP must have a negative pregnancy test before each vaccination. If menopausal status is unclear, a pregnancy test is required.
Inclusion into the open label safety extension
- Receipt of at least one (1) vaccination prior to Day 42.
Exclusion Criteria:
Subjects will not be eligible for study participation if they meet any of the exclusion criteria:
- History of an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses.
- History of ongoing clinical condition or medication or treatments that may adversely affect the immune system.
- Subjects with pulse oximetry <90% at screening and prior to each vaccination.
- Individuals who are antigen positive, seropositive or reverse transcriptase polymerase chain reaction (RT-PCR) positive for SARS-CoV-2, including prior to a second dose of PTX-COVID19-B.
- Individuals who are at increased risk of exposure to SARS-CoV-2 (e.g., healthcare workers, emergency responders).
- Close contact of anyone known to have SARS-CoV-2 infection within 30 days prior to vaccine administration.
- Individuals with any elevated (Grade 1 or higher) laboratory test assessed as clinically significant for age/sex by the investigator at screening.
- Individuals known to have anti-platelet antibodies.
- Individuals with myocarditis and/or arrythmias.
- Active neoplastic disease (excluding non-melanoma skin cancer that was successfully treated) or a history of any hematological malignancy. ("Active" is defined as having received treatment within the past five years).
- Long-term (> two (2) weeks) use of oral or parenteral steroids or high-dose inhaled steroids (> 800 μg/day of beclomethasone dipropionate or equivalent) within six months before screening (nasal and topical steroids are allowed).
- History of autoimmune, inflammatory disease, or potential immune-mediated medical conditions (PIMMCs).
- Women currently pregnant, lactating, or planning a pregnancy between enrollment and Day 42.
- History of immune thrombocytopenic purpura (ITP).
- History of Guillain-Barré Syndrome or any degenerative neurology disorder.
- History of anaphylactic-type reaction to any injected vaccines.
- Known or suspected hypersensitivity to one or more of the components of the vaccine.
- Known history of alcohol abuse, illicit drug use, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of screening.
- Acute illness or fever (temperature >37.5C) within three (3) days before study enrollment (enrollment may be delayed for full recovery if acceptable to the investigator and within Protocol-defined windows).
- Individuals currently participating or planning to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, or medication); or who have received an experimental agent within one (1) month (three (3) months for immunoglobulins) before enrollment in this study; or who expect to receive another experimental agent up to Day 90 in this study.
- Receipt of immunoglobulin or another blood product within the three (3) months before enrollment in this study or those who expect to receive immunoglobulin or another blood product during this study.
- Individuals using prescription medications for prophylaxis of SARS-CoV-2.
- Individuals who plan to receive another vaccine within the first three (3) months of the study (except influenza vaccine which should not be given within two (2) weeks of vaccine).
- Receipt of any other SARS-CoV-2 or other experimental coronavirus (MERS, SARS etc.) vaccine at any time prior to or during the study.
- Receipt of any investigational vaccine or investigational drug within one (1) month of enrollment and through the end of the study (one (1) year after the last vaccination).
- Planning international travel from enrollment through Day 43.
- History of surgery or major trauma within 12 weeks of screening, or surgery planned during the study.
- Significant blood loss (> 400 mL) or has donated one or more units of blood (within 56 days for males and 84 days for females) or plasma (within two (2) weeks) prior to study participation.
- Positive urine drugs of abuse screen test result.
- Positive screen for HIV-1 and HIV-2 antibodies, HBsAg, or HCV antibody.
- Involved in the planning or conduct of this study.
Unwilling or unlikely to comply with the requirements of the study.
Exclusion from the open label safety extension:
- Participation in a study that would affect potential immunogenicity evaluation during ongoing participation in this study. Participation in any other study is allowed after Day 90.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 40µg PTX-COVID19-B Open-label
Participants, 15 healthy adults 18 to 64 years of age will receive 1 intramuscular (IM) injection of 40µg PTX-COVID19-B vaccine on Day 1, followed by a second dose on Day 28.
|
Sterile solution for injection
|
Experimental: 40µg PTX-COVID19-B
Participants, 360 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of 40µg PTX-COVID19-B vaccine on Day 1, followed by a second dose on Day 28.
Participants will receive a placebo dose on Day 21.
|
0.9% sodium chloride (normal saline) injection
Sterile solution for injection
|
Active Comparator: Pfizer-BioNTech COVID-19 vaccine
Participants, 190 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of Pfizer-BioNTech COVID-19 vaccine on Day 1, followed by a placebo dose on Days 21.
Participants will receive a placebo dose on Day 28.
|
0.9% sodium chloride (normal saline) injection
Sterile solution for injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Injection Site Reactions
Time Frame: Day 1 through Day 42
|
Injection site reactions (e.g., arm check evaluations including pain, tenderness, erythema/redness, induration/swelling) through the seventh day post each vaccination
|
Day 1 through Day 42
|
Incidence of Solicited Adverse Events (AEs)
Time Frame: Day 1 through Day 7 for each dose administration
|
Incidence of solicited adverse events (AEs) (e.g., fever, chills, nausea/vomiting, diarrhea, headache, fatigue, myalgia) through the seventh day post each vaccination and Serious Adverse Events (SAEs)
|
Day 1 through Day 7 for each dose administration
|
Assessment of AEs
Time Frame: Day 1 through Day 42
|
Incidence of unsolicited AEs and SAEs
|
Day 1 through Day 42
|
Assessment of Safety
Time Frame: Day 1 through Day 42
|
Medically attended AEs New onset chronic disease SAEs, AEs of special interest Potential immune-mediated medical conditions |
Day 1 through Day 42
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO-CL-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19 Vaccine
-
Gamaleya Research Institute of Epidemiology and...Moscow Healthcare DepartmentRecruitingCovid19 | Vaccine Preventable DiseaseRussian Federation
-
National University Hospital, SingaporeAgency for Science, Technology and Research; National University of SingaporeUnknownCovid19 | Breastfeeding | Vaccine Exposure Via Breast MilkSingapore
-
Xavier University of Louisiana.CompletedCovid19 | Vaccine Hesitancy | Vaccine RefusalUnited States
-
Masaryk UniversityRecruitingAdverse Reaction to Vaccine | COVID19 VaccinePoland, Canada, United States, Croatia, Czechia, Estonia, Ethiopia, Germany, Ghana, Mexico, Portugal, Russian Federation, Serbia, Slovenia
-
Rajavithi HospitalDepartment of Medical servicesWithdrawnCovid19 | Covid19 Vaccine
-
Stanford UniversityActive, not recruitingVaccine Hesitancy | Vaccine Refusal | Vaccine KnowledgeKenya
-
Children's Mercy Hospital Kansas CityCompletedVaccine Hesitancy | Vaccine RefusalUnited States
-
University of OttawaNot yet recruitingPneumococcal Vaccine Uptake | Vaccination Willingness | Pneumococcal Vaccine Knowledge | Pneumococcal Vaccine AttitudeCanada
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHPV Vaccine Attitudes | HPV Vaccine IntentionUnited States
-
University of PittsburghMerck Sharp & Dohme LLCCompletedQuadrivalent HPV Vaccine | Human Papillomavirus VaccineUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States